GB Sciences IncOTCQB:GBLX
- LAST PRICE0.0067
- TODAY'S CHANGE (%)0.0005 (8.7097%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0067 / 0.0062
- Day Range
- 52 Week Range
- Volume167,562
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GBLX |
|---|---|---|
| 09:32 ET | 5000 | 0.0067 |
| 09:44 ET | 2000 | 0.0065 |
| 10:04 ET | 6200 | 0.00664 |
| 10:08 ET | 3300 | 0.0067 |
| 10:33 ET | 5500 | 0.00664 |
| 12:42 ET | 100 | 0.00664 |
| 12:48 ET | 910 | 0.0067 |
| 01:09 ET | 1000 | 0.00664 |
| 01:22 ET | 129750 | 0.00664 |
| 02:02 ET | 1000 | 0.00658 |
| 02:05 ET | 5000 | 0.0069 |
| 02:18 ET | 2800 | 0.00664 |
| 03:33 ET | 5000 | 0.00674 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
GB Sciences Inc | 2.7M | -0.6x | --- |
Salarius Pharmaceuticals Inc | 2.7M | -0.1x | --- |
Allarity Therapeutics Inc | 2.7M | 0.0x | --- |
Phio Pharmaceuticals Corp | 2.7M | -0.1x | --- |
Ampio Pharmaceuticals Inc | 2.7M | -0.3x | --- |
Zyversa Therapeutics Inc | 2.6M | 0.0x | --- |
Company Information
GB Sciences, Inc. is a biopharmaceutical research and development company. The Company develops disease-targeted formulations of cannabis and other plant-inspired therapeutic mixtures for the prescription drug market through its wholly owned subsidiary, GbS Global Biopharma, Inc. (GBSGB). The Company's primary focus is on preparing its lead program for the treatment of the motor symptoms of Parkinson's disease (PD) in a human clinical trial. Through GBSGB, the Company is engaged in the research and development of plant-inspired medicines, with virtual operations in North America and Europe. GBSGB has a portfolio of intellectual property containing both plant-inspired formulations and its artificial intelligence (AI)-enabled drug discovery platform, as well as research contracts and various supplier arrangements. GBSGBs intellectual property covers a range of over 65 medical conditions, from which five drug development programs are in the preclinical stage of drug development.
Contact Information
- Headquarters
- 6450 Cameron St Ste 110ALAS VEGAS, NV, United States 89118-4337
- Phone
- 888-895-3594
- Fax
- ---
Executives
- Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer
- John Poss
- President, Chief Science Officer
- Andrea Small-Howard
- Company Secretary
- Gary Henrie
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 402.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.29 |
EPS | $-0.01 |
Book Value | $-0.01 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
